You are here: Home » Current Affairs » News » National
Business Standard

Look forward to broad MoU to enhance health partnership with India, says US

The US on Monday crossed the grim milestone of 500,000 COVID-19 deaths. With 28,184,218 coronavirus cases and 500,172 deaths due to the disease so far, as recorded by Johns Hopkins University

US India relations  | Health sector

Press Trust of India  |  Washington 

Union Health Minister Harsh Vardhan at the 4th FII Summit
Union Health Minister Harsh Vardhan at the 4th FII Summit

The US has said it is looking forward to an "overarching" memorandum of understanding to enhance health partnership with India and asserted that the cooperation between the two countries on COVID-19 builds on decades of successful collaboration in health and biomedical research.

The US on Monday crossed the grim milestone of 500,000 COVID-19 deaths. With 28,184,218 cases and 500,172 deaths due to the disease so far, as recorded by Johns Hopkins University, America is the worst-affected nation.

"We look forward to an overarching MoU to enhance health cooperation between our two countries (US and India). We are working together on developing diagnostics, therapeutics, vaccines to combat the disease (COVID-19) and to recognise the importance of manufacturing critical drugs during this time and making them accessible globally," State Department Spokesperson Ned Price told reporters at his daily news conference on Monday.

The total number of cases in India stands at 1,10,05,850 -- the second in the world after the US. The death toll is 1,56,385 -- fourth globally.

India's pharmaceutical sector is strong and well-established and has long played a central role in manufacturing life saving vaccines for global use. We are pleased that the US pharmaceutical industry has been coordinating with Indian companies since the beginning of this pandemic, Price said, responding to a question on India donating and supplying domestically manufactured COVID-19 vaccines to several countries across the globe.

Known as the 'pharmacy of the world', India produces 60 per cent of vaccines globally. India has sent consignments of domestically manufactured vaccines to several countries, including Nepal, Bangladesh, Bhutan, the Maldives, Seychelles, Myanmar, Mauritius, Oman, Saudi Arabia, Bahrain, South Africa, Brazil and Morocco.

When it comes to the broad issue of coordination between the United States and India on COVID-19, I would say that cooperation between our two countries builds on decades of successful partnership in health and biomedical research, Price said.

The US is partnering with India to strengthen the global response to COVID-19 -- ranging from addressing infectious disease outbreaks, strengthening health systems to securing global supply chains, he said.

India and the US recently welcomed an initiative to collaborate on infectious disease, including COVID-19 and other emerging threats, through the International Centre of Excellence and Research, Price said.

In a recent op-ed in Newsweek magazine, India's Ambassador to the US, Taranjit Singh Sandhu, wrote that in recent years, India has emerged as the "pharmacy of the world", with great capabilities in bulk production of generic drugs and vaccines, in addition to its experience immunising a large population.

India recently stepped up to provide vaccines to neighbouring countries and other partners, including in Africa, Latin America, the Middle East and Asia, he said.

The US has resources and scientific capabilities that make it a natural, complementary partner in supporting a number of other countries seeking to fight the pandemic, Sandhu wrote.

Furthermore, from the provision of active pharmaceutical ingredients to generic medicines that have lowered drug prices and created jobs and investments, India has demonstrated its reliability as a supply chain partner, especially as de-risking from single country supplies has become a priority, he said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, February 23 2021. 07:20 IST